

Supplementary material

A study on the side effects caused by the Pfizer/BioNTech COVID-19 vaccine: Focus on IgG antibodies and serological biomarkers

Supplementary Table 1. Demographic characteristics for the study population ($N = 502$). Data presented as number (n) and percentage (%). Significant at $p \leq 0.05$

Characteristics	Vaccines (Pfizer/BioNTech)				p
	First dose		Second dose		
	n	%	n	%	
Age					
20-39	60	12	60	12	0.0168
40-59	277	55	277	55	
≥ 60	165	33	165	33	
Sex					
Male	262	52	262	52	ns
Female	240	48	240	48	
Clinical parameters					
IgG	182	36	489	97	< 0.0001
CRP	153	30	232	46	< 0.0001
WBC	135	27	122	24	0.3995
D-dimer	116	23	84	17	0.3957
Side Effects					
Injection site pain	226	45	330	66	< 0.0001
Headache	202	40	268	53	
Fever	203	40	205	41	
Myalgia	42	8	250	50	
Nausea	56	11	287	57	
Fatigue	21	6	238	47	
Comorbidities					
Comorbidities	244		48.6		< 0.0001
Hypertension	146	29	146	29	
Diabetes	129	26	129	26	
Thyroid disease	67	13	67	13	
Cardiovascular disease	33	7	33	7	
Cancer	40	8	40	8	
Healthy	258		51.4		




Fig. 1. Gender distribution of post-vaccinated participants (morbid and healthy)




Fig. 2. **A)** Age distribution of enrolled participants; **B)** Age and gender distribution in both groups: healthy vs. comorbidities




Fig. 3. A) Incidence of IgG generation in D1 and D2 vaccination; B) IgG antibody distribution in both groups: healthy vs. morbid




Fig. 4. Prevalence of COVID-19 vaccination side effects with IgG generation and number of patients